| Industry Symposia
|
|
|
|
Thanks to WCN’22 sponsors for hosting today’s industry symposia:
|
Sanofi:
Vascular Calcification in CKD - The Hidden Threat
|
|
Zydus Cadila:
HIF-PH Inhibitors - a Novel Option for Anemia Management-Expectations and
Potential Concerns
|
|
Baxter Malaysia:
Rise of Baxter’s Advanced Therapies
|
|
Novartis:
A Focus on IgAN - Evolving Challenges and Therapeutic Advances
|
|
Fresenius Medical Care:
Water Quality for Hemodialysis: An Urgent Need in Developing Economies to Ensure
Patient Safety
|
|
AstraZeneca:
The Evidence-Based CKD Clinic: Changing Practice with SGLT2 Inhibition
|
|
Excel Continuing Education:
Shortening the Path to an aTTP Diagnosis in the Nephrology Clinical Setting
|
|
GSK:
Patient Report Outcome Measures (PROMs) in practice: how and why you should
consider adding PROMs to your routine Chronic Kidney Disease (CKD) care
|
|
Calliditas Therapeutics:
Looking Upstream in IgAN: The Role of the Gut and its Implications
|
|
Chinook Therapeutics:
New Frontiers in the Treatment of Glomerular Diseases
|
|
|
Industry Symposia are open-access. Available on-demand on the WCN platform
until May 31, 2022.
|
|
|